Eupraxia Pharmaceuticals Announces Additional Positive Clinical Data From Phase 1b/2a RESOLVE Trial Evaluating EP-104GI For Eosinophilic Esophagitis (EoE) - Press Release
$EPRX
Pharmaceuticals and Biotechnology
Health Care
- Trial's first and second cohorts maintaining signs of potential efficacy out to 24 weeks
- Data from the second cohort showed improvements in eosinophil counts and histological scores out to 12 weeks suggesting a dose response over the first cohort
- Data from the trial's third cohort suggest improvements in patient-reported symptoms and histological outcomes at 12 weeks
- EP-104GI showed an encouraging safety profile in all three cohorts